News

The FDA’s approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
Moderna's next COVID-19 vaccine has received Food and Drug Administration approval, albeit with restrictions not placed on ...
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...
Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 ...
After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up ...
By Christina Jewett and Apoorva Mandavilli The Food and Drug Administration on Friday approved the Novavax Covid-19 vaccine, but only for older adults and for others over age 12 who have at least ...